June 13, 2018 / 8:41 PM / 6 months ago

FDA finds deficiencies in Mylan's generic Advair

June 13 (Reuters) - U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

Mylan said here it expects to receive a formal complete response letter from the U.S. Food And Drug Administration on June 27 and would determine what impact, if any, it would have on its full-year forecast.

The company's shares fell 4 percent to $40.00 after the bell. (Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below